PMID- 10502722
OWN - NLM
STAT- MEDLINE
DCOM- 19991021
LR  - 20190708
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 84
IP  - 5
DP  - 1999 Oct 22
TI  - Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in 
      human endometrial carcinomas.
PG  - 470-7
AB  - We examined production and tissue localization of 7 different matrix
      metalloproteinases (MMP-1, -2, -3, -7, -8, -9 and -13) and 2 tissue inhibitors of
      metalloproteinases (TIMP-1 and -2) in human endometrial-carcinoma tissues.
      Sandwich enzyme immunoassays showed enhanced production of MMP-7, MMP-8 and MMP-9
      as well as TIMP-1 in the carcinoma tissues compared with non-carcinoma
      endometrial tissues. Among these MMPs, only the amount of MMP-7 correlated with
      clinicopathological factors of the carcinomas. The level was significantly
      6.8-fold higher in the patient group with lymph-node metastases than in that
      without metastases (p < 0.05), and also increased with the progress of the
      clinical stage. MMP-7 was immunolocalized predominantly to the carcinoma cells in
      73% of the cases, while MMP-8 and MMP-9 were immunostained in the inflammatory
      cells infiltrated in the carcinoma tissues. Immunoblotting revealed a definite
      band for the zymogen of MMP-7 (proMMP-7) of 28 kDa in 82% of the carcinoma
      samples, while only a faint band for proMMP-7 was seen in 57% of the
      non-carcinoma endometrial samples. Active MMP-7 species of 19 kDa and its
      activity were demonstrated in the carcinoma samples with proMMP-7 production by
      immunoblotting and zymography, respectively. RT-PCR using a specific primer pair 
      for MMP-7 demonstrated expression in 86% of the carcinoma tissue and in 57% of
      the control tissue samples. In situ hybridization showed carcinoma cells
      selectively expressing MMP-7 mRNA. These data suggest that, among the 7 MMPs
      examined, MMP-7 may play a key role in invasion and lymph-node metastasis of
      human endometrial carcinomas.
CI  - Copyright 1999 Wiley-Liss, Inc.
FAU - Ueno, H
AU  - Ueno H
AD  - Department of Molecular Immunology and Pathology, Cancer Research Institute,
      Kanazawa University, Kanazawa, Japan.
FAU - Yamashita, K
AU  - Yamashita K
FAU - Azumano, I
AU  - Azumano I
FAU - Inoue, M
AU  - Inoue M
FAU - Okada, Y
AU  - Okada Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (RNA, Messenger)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2)
RN  - EC 3.4.24.- (Metalloendopeptidases)
RN  - EC 3.4.24.23 (Matrix Metalloproteinase 7)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Endometrial Neoplasms/*enzymology
MH  - Enzyme Activation
MH  - Female
MH  - Humans
MH  - Immunoblotting
MH  - Immunoenzyme Techniques
MH  - Lymphatic Metastasis
MH  - Matrix Metalloproteinase 7
MH  - Metalloendopeptidases/analysis/*biosynthesis/genetics
MH  - Middle Aged
MH  - RNA, Messenger/analysis
MH  - Tissue Inhibitor of Metalloproteinase-1/analysis
MH  - Tissue Inhibitor of Metalloproteinase-2/analysis
EDAT- 1999/09/30 00:00
MHDA- 1999/09/30 00:01
CRDT- 1999/09/30 00:00
PHST- 1999/09/30 00:00 [pubmed]
PHST- 1999/09/30 00:01 [medline]
PHST- 1999/09/30 00:00 [entrez]
AID - 10.1002/(SICI)1097-0215(19991022)84:5<470::AID-IJC4>3.0.CO;2-D [pii]
AID - 10.1002/(sici)1097-0215(19991022)84:5<470::aid-ijc4>3.0.co;2-d [doi]
PST - ppublish
SO  - Int J Cancer. 1999 Oct 22;84(5):470-7. doi:
      10.1002/(sici)1097-0215(19991022)84:5<470::aid-ijc4>3.0.co;2-d.